Floatz logo

Safinamide

Tardive Dyskinesia

Zambon SpASmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Tardive Dyskinesia cohort.

Asset / SponsorPhaseRating
MT-5199
Neurocrine Biosciences
Phase 4BBB
Ginkgo Biloba
Beijing HuiLongGuan Hospital
Phase 3BB
VARENICLINE
Corporal Michael J. Crescenz VA Medical Center
Phase 4B
Pyridoxol
Beersheva Mental Health Center
Phase 3B
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-
Novartis Pharmaceuticals
Phase 2B

View all 14 →

Same molecule, other indications

Safinamide is also rated in:

Parkinson diseaseDormant
A
Indicative · Phase 4
83 / 100
View asset →
kidney failureDormant
CC
Indicative · Phase 1
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →